ES2569185T3 - Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer - Google Patents

Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer Download PDF

Info

Publication number
ES2569185T3
ES2569185T3 ES12709146.0T ES12709146T ES2569185T3 ES 2569185 T3 ES2569185 T3 ES 2569185T3 ES 12709146 T ES12709146 T ES 12709146T ES 2569185 T3 ES2569185 T3 ES 2569185T3
Authority
ES
Spain
Prior art keywords
alkyl
compound
pharmaceutically acceptable
fluoro
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12709146.0T
Other languages
English (en)
Spanish (es)
Inventor
Christopher Mcguigan
Jan Balzarini
Magdalena SLUSARCYZK
Blanka GONCZY
Paola MURZIANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucana PLC
Original Assignee
Nucana Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45841523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2569185(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1103582.1A external-priority patent/GB201103582D0/en
Priority claimed from GBGB1105660.3A external-priority patent/GB201105660D0/en
Application filed by Nucana Biomed Ltd filed Critical Nucana Biomed Ltd
Application granted granted Critical
Publication of ES2569185T3 publication Critical patent/ES2569185T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES12709146.0T 2011-03-01 2012-02-29 Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer Active ES2569185T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1103582.1A GB201103582D0 (enExample) 2011-03-01 2011-03-01
GB201103582 2011-03-01
GBGB1105660.3A GB201105660D0 (en) 2011-04-01 2011-04-01 Chemical compounds
GB201105660 2011-04-01
PCT/GB2012/050457 WO2012117246A1 (en) 2011-03-01 2012-02-29 Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
ES2569185T3 true ES2569185T3 (es) 2016-05-09

Family

ID=45841523

Family Applications (4)

Application Number Title Priority Date Filing Date
ES18178715T Active ES2903097T3 (es) 2011-03-01 2012-02-29 Formulación farmacéutica que comprende un derivado de fosforamidato de 5-fluoro-2'-desoxiuridina para su uso en el tratamiento del cáncer
ES21209926T Active ES3039965T3 (en) 2011-03-01 2012-02-29 Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
ES12709146.0T Active ES2569185T3 (es) 2011-03-01 2012-02-29 Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
ES16150494.9T Active ES2686219T3 (es) 2011-03-01 2012-02-29 Compuestos químicos

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES18178715T Active ES2903097T3 (es) 2011-03-01 2012-02-29 Formulación farmacéutica que comprende un derivado de fosforamidato de 5-fluoro-2'-desoxiuridina para su uso en el tratamiento del cáncer
ES21209926T Active ES3039965T3 (en) 2011-03-01 2012-02-29 Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16150494.9T Active ES2686219T3 (es) 2011-03-01 2012-02-29 Compuestos químicos

Country Status (28)

Country Link
US (7) US8933053B2 (enExample)
EP (4) EP3447061B1 (enExample)
JP (1) JP5978232B2 (enExample)
KR (1) KR101885940B1 (enExample)
CN (2) CN103403013B (enExample)
AU (1) AU2012223012C1 (enExample)
BR (1) BR112013021986B1 (enExample)
CA (1) CA2828326C (enExample)
CL (1) CL2013002517A1 (enExample)
CY (2) CY1117445T1 (enExample)
DK (3) DK2681227T3 (enExample)
ES (4) ES2903097T3 (enExample)
HR (2) HRP20160346T1 (enExample)
HU (2) HUE029022T2 (enExample)
IL (1) IL228169A (enExample)
LT (1) LT3447061T (enExample)
MX (1) MX339822B (enExample)
NZ (1) NZ615270A (enExample)
PH (2) PH12013501723A1 (enExample)
PL (3) PL3447061T3 (enExample)
PT (2) PT3447061T (enExample)
RS (2) RS54776B1 (enExample)
RU (1) RU2614406C2 (enExample)
SG (1) SG192841A1 (enExample)
SI (2) SI2681227T1 (enExample)
SM (2) SMT202100715T1 (enExample)
WO (1) WO2012117246A1 (enExample)
ZA (2) ZA201306468B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
EP3447061B1 (en) 2011-03-01 2021-11-24 NuCana plc Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
AU2013346515B2 (en) 2012-11-16 2017-05-25 NuCana plc Process for preparing nucleoside prodrugs
WO2015013352A2 (en) * 2013-07-25 2015-01-29 Patel Hasmukh B Nucleoside phosphoramidates and phosphoramidites
CN104447923B (zh) * 2013-09-23 2018-03-30 中国药科大学 2’‑脱氧‑2’‑氟‑2’‑甲基核苷衍生物及其制备方法与在制药中的用途
RU2553996C1 (ru) * 2013-11-27 2015-06-20 Андрей Александрович Иващенко Замещенные (2r,3r,5r)-3-гидрокси-(5-пиримидин-1-ил)тетрагидрофуран-2-илметил арил фосфорамидаты
SG11201608303QA (en) 2014-04-04 2016-11-29 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
JP2017516779A (ja) * 2014-05-28 2017-06-22 アイデニクス・ファーマシューティカルズ・エルエルシー 癌治療のためのヌクレオシド誘導体
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
MY183198A (en) 2014-06-25 2021-02-18 Nucana Biomed Ltd Gemcitabine prodrugs
PL225283B1 (pl) * 2014-07-24 2017-03-31 Univ Im Adama Mickiewicza W Poznaniu Pochodne 2,3’-anhydro-2’-deoksy-5-fluorourydyny o działaniu cytotoksycznym, sposób wytwarzania i zastosowanie
EA031727B1 (ru) 2014-11-28 2019-02-28 НУКАНА ПиЭлСи Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
KR102363946B1 (ko) 2015-03-06 2022-02-17 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
CN108368147A (zh) * 2015-05-27 2018-08-03 南方研究院 用于治疗癌症的核苷酸
MX2018005872A (es) 2015-11-16 2019-05-16 Ichorion Therapeutics Inc Profarmacos de acido nucleico.
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
HRP20220278T1 (hr) 2016-09-07 2022-05-13 Atea Pharmaceuticals, Inc. 2'-supstituirani-n6-supstituirani purinski nukleotidi za liječenje bolesti izazvanih rnk virusima
CN110087666B (zh) 2016-11-13 2024-04-30 想象制药公司 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法
CN109863160B (zh) 2016-12-23 2022-06-07 四川科伦博泰生物医药股份有限公司 核苷磷酸类化合物及其制备方法和用途
RU2644156C1 (ru) * 2017-02-28 2018-02-08 Александр Васильевич Иващенко Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN111315446A (zh) 2017-08-08 2020-06-19 中山大学 用于治疗多药耐药性肿瘤的方法和组合物
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
GB201715011D0 (en) * 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
CN111836823B (zh) * 2018-03-09 2023-06-30 国立研究开发法人科学技术振兴机构 β修饰磷酸化合物前体、β修饰磷酸化合物、反应阻碍剂和包含这些化合物的医药品以及反应阻碍方法
CN110387226A (zh) * 2018-04-20 2019-10-29 天津大学 一种用于检测肿瘤的荧光探针及用途
US12221649B2 (en) * 2018-11-30 2025-02-11 The University Of Tokyo Fluorescent probe for detecting carboxypeptidase activity
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
CN110840907B (zh) * 2019-08-16 2022-11-25 南京医科大学 一类自由基敏感的尿嘧啶类ProTide前药及其药物用途
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN116368143A (zh) * 2020-08-31 2023-06-30 埃莫里大学 5'-取代的单磷酸核苷、其前药及其相关用途
EP4630433A1 (en) 2022-12-07 2025-10-15 NuCana plc Synthesis of nucleoside derivative nuc-3373

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US1002239A (en) 1902-04-11 1911-09-05 Stromberg Carlson Telephone Telephone system.
US2945038A (en) 1956-09-26 1960-07-12 Hoffmann La Roche 5-fluorocytosine and preparation thereof
US3201387A (en) 1963-09-18 1965-08-17 Heidelberger Charles 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same
US3792039A (en) 1971-12-27 1974-02-12 Miles Lab Poly 2'-fluoro-2'-deoxyuridylic acid
DD279248A1 (de) 1989-01-01 1990-05-30 Akad Wissenschaften Ddr Verfahren zur herstellung von 2',3'-didesoxythymidin-5'-diamidophosphaten
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
RU2197964C2 (ru) * 1995-04-12 2003-02-10 Дзе Проктер Энд Гэмбл Компани Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций
WO1999037753A1 (en) 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CN1390227A (zh) 1999-07-22 2003-01-08 新生物生物公司 酶催化的治疗活化
DE10109657A1 (de) 2001-02-28 2002-09-05 Menarini Ricerche Spa Verfahren zur Herstellung von (E)-5-(2-Bromvinyl)-2`-desoxyuridin
WO2003000713A1 (en) 2001-06-21 2003-01-03 Glaxo Group Limited Nucleoside compounds in hcv
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
US8399428B2 (en) 2004-12-09 2013-03-19 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
JP2009504704A (ja) 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート
WO2007056596A2 (en) 2005-11-09 2007-05-18 Wayne State University Phosphoramidate derivatives of fau
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
CN101922935B (zh) 2010-07-16 2012-07-18 北京大学 一种最小互易结构干涉型全光纤陀螺仪
EP2596004B1 (en) 2010-07-19 2014-09-10 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2810928A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
WO2012117027A1 (en) 2011-03-01 2012-09-07 Janssen Pharmaceutica Nv 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
EP3447061B1 (en) * 2011-03-01 2021-11-24 NuCana plc Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
NO3119794T3 (enExample) 2014-06-25 2018-03-10
EA031727B1 (ru) 2014-11-28 2019-02-28 НУКАНА ПиЭлСи Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
TR201806642T4 (tr) 2015-05-14 2018-06-21 NuCana plc Kanser tedavileri.
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Also Published As

Publication number Publication date
US10993957B2 (en) 2021-05-04
CN104974206B (zh) 2019-08-23
IL228169A (en) 2016-07-31
SMT202100715T1 (it) 2022-01-10
US20220023330A1 (en) 2022-01-27
RS54776B1 (sr) 2016-10-31
WO2012117246A1 (en) 2012-09-07
PH12015500485B1 (en) 2017-04-10
ZA201306468B (en) 2015-04-29
US11559542B2 (en) 2023-01-24
CA2828326A1 (en) 2012-09-07
PH12013501723A1 (en) 2013-10-07
BR112013021986B1 (pt) 2021-07-27
PL2681227T3 (pl) 2016-08-31
US20170312302A1 (en) 2017-11-02
US20230165886A1 (en) 2023-06-01
PH12015500485A1 (en) 2017-04-10
ES2686219T3 (es) 2018-10-16
BR112013021986A2 (pt) 2016-11-16
JP5978232B2 (ja) 2016-08-24
EP3447061B1 (en) 2021-11-24
PT3447061T (pt) 2021-12-23
CN103403013B (zh) 2016-03-16
MX339822B (es) 2016-06-13
EP2681227A1 (en) 2014-01-08
US9655915B2 (en) 2017-05-23
PT3031812T (pt) 2018-10-18
HUE060127T2 (hu) 2023-02-28
HRP20160346T1 (hr) 2016-05-06
US20160166596A1 (en) 2016-06-16
RU2614406C2 (ru) 2017-03-28
EP3447061A1 (en) 2019-02-27
RS62721B1 (sr) 2022-01-31
RU2013143862A (ru) 2015-04-10
PL3031812T3 (pl) 2018-12-31
AU2012223012A1 (en) 2013-05-02
EP4023299A1 (en) 2022-07-06
ZA201409013B (en) 2016-02-24
EP4023299C0 (en) 2025-08-20
CL2013002517A1 (es) 2014-07-25
SMT201600132B (it) 2016-07-01
DK3447061T3 (da) 2022-01-03
MX2013009815A (es) 2014-03-21
US20140057866A1 (en) 2014-02-27
ES3039965T3 (en) 2025-10-28
LT3447061T (lt) 2022-01-25
SG192841A1 (en) 2013-09-30
CY1124871T1 (el) 2022-11-25
CY1117445T1 (el) 2017-04-26
AU2012223012C1 (en) 2015-09-03
PL3447061T3 (pl) 2022-01-31
DK2681227T3 (da) 2016-02-22
EP2681227B1 (en) 2016-02-10
DK3031812T3 (en) 2018-09-17
CA2828326C (en) 2019-05-07
KR101885940B1 (ko) 2018-08-06
US10022390B2 (en) 2018-07-17
HRP20211967T1 (hr) 2022-03-18
SI2681227T1 (sl) 2016-04-29
CN104974206A (zh) 2015-10-14
US8933053B2 (en) 2015-01-13
KR20140023913A (ko) 2014-02-27
US9221866B2 (en) 2015-12-29
HK1192758A1 (zh) 2014-08-29
ES2903097T3 (es) 2022-03-31
US20150183817A1 (en) 2015-07-02
EP3031812B1 (en) 2018-08-01
AU2012223012B2 (en) 2015-06-18
NZ615270A (en) 2015-09-25
EP4023299B1 (en) 2025-08-20
EP3031812A1 (en) 2016-06-15
US11925658B2 (en) 2024-03-12
CN103403013A (zh) 2013-11-20
SI3447061T1 (sl) 2022-02-28
US20190201432A1 (en) 2019-07-04
HUE029022T2 (en) 2017-02-28
JP2014506913A (ja) 2014-03-20

Similar Documents

Publication Publication Date Title
ES2569185T3 (es) Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
ES2641761T3 (es) Procedimientos para preparar inhibidores JAK y compuestos intermedios relacionados
Wu et al. Efficient and phosphine-free bidentate N-heterocyclic carbene/ruthenium catalytic systems for the dehydrogenative amidation of alcohols and amines
Rodríguez et al. Directed ortho-lithiation of unprotected diphenylphosphinic acids
Li et al. Photo-mediated synthesis of 1, 2-dideoxy-2-phosphinylated carbohydrates from glycals: the reduction of glycosyl radicals to glycosyl anions
Kumar et al. Microwave-assisted cleavage of phosphate, phosphonate and phosphoramide esters
Jindřich et al. Synthesis of N-(3-fluoro-2-phosphonomethoxypropyl)(FPMP) derivatives of heterocyclic bases
Zakirov et al. Synthesis of spin-labeled bispidines
Tesson et al. Synthesis of (1S, 2S)-and (1R, 2R)-1-amino-2-methylcyclopropane-phosphonic acids from racemic methylcyclopropanone acetal
Zhao et al. Axially chiral phosphine–oxazoline ligands in silver (I)-catalyzed asymmetric Mannich reaction of N-Boc aldimines with trimethylsiloxyfuran
Kimura et al. Studies on nucleosides and nucleotides. VIII. Preparation and reactions of triphenylphosphoranediylnucleosides.
Egorov et al. Phosphorylation of Benzimidazole-2-thiones by Chloroethynylphosphonate
ES2601849T3 (es) Sintones de fosfonatos para la síntesis de derivados de fosfonatos que muestran mejor biodisponibilidad
Musiyak et al. Synthesis of new purine derivatives containing α-and ω-amino acid fragments
Chen et al. Synthesis and properties of novel amino acid linked phosphoryl nitrogen mustard derivatives
Jiménez‐Osés et al. A novel multistep mechanism for the stereocontrolled ring opening of hindered sulfamidates: mild, green, and efficient reactivity with alcohols
Green et al. The preparation and characterization of some fluorinated α-aminoarylmethanephosphonic acids
Kasthuri et al. Synthesis of (R)-and (S)-β-hydroxyphosphonate acyclonucleosides: structural analogues of Adefovir (PMEA)
Alauddin et al. Synthesis of [18F]‐labeled N‐3 (substituted) thymidine analogues: N‐3 ([18F] fluorobutyl) thymidine ([18F]‐FBT) and N‐3 ([18F] fluoropentyl) thymidine ([18F]‐FPT) for PET
Metlushka et al. Phosphorylation of betti base with diethyl chlorophosphate.
Kondratyuk et al. Synthesis and some properties of 4-phosphorylated derivatives of 5-mercapto-1, 3-oxazoles
JP5067752B2 (ja) リン酸エステルの製造方法
Morales et al. Linear Synthesis of Chiral cycloSal‐Pronucleotides
Cui et al. The diastereoselective synthesis of methyl 5-deoxy-5-(dialkylphosphono)-5-(dialkylphosphorylamido)-2, 3-O-isopropylidene-β-d-ribofuranosides
Liu et al. Diastereoselective synthesis of 1, 10-dihydropyrrolo [1, 2-a][1, 10] phenanthroline derivatives via 1, 3-dipolar cycloaddition reaction